Does This Drug Represent “A Paradigm Shift for Small Molecule Drug Development?”

Greg Crimmins, founder and CEO of Remedy Plan Therapeutics, discusses the role of NAMPT in cancer, the challenges of developing NAMPT inhibitors without toxicity, and why he believes the company has solved the problem.